Phase 2 RCT in 65 adults with PTSD: TSND-201 (methylone) improved CAPS-5 total severity at day 64 vs placebo (LS mean difference 9.64; P=.01), with improvements in secondary outcomes PCL-5, SDS and MADRS. Common adverse events included headache, nausea and raised blood pressure.
RCTn = 65
Jones et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial